Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atazanavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | CTSD | P07339 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CTSE | P14091 | 1/20 | 0.41 |
| ▸ | PGC | P20142 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atazanavir SCHEMBL41697 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL9975220 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL825777 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL7993264 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1559640 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1396072 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 1.00 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25138 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2004028455-A2 | MONOACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| WO-2004029201-A2 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | FRONTIER BIOTECHNOLOGIES CO., LTD (CN) | 2004-04-08 | — | — | WO | claimed |
| WO-2004024683-A2 | COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR | UNIVERSITY OF MARYLAND BIOTECHNOLOGY (US) | 2004-03-25 | — | — | WO | claimed |
| WO-2004002498-A1 | ANTIVIRAL REGIMENS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | claimed |
| WO-2003085127-A2 | METHOD FOR IDENTIFICATION OF INSULIN RECEPTOR KINASE ACTIVATORS | TELIK, INC. (US) | 2003-10-16 | — | — | WO | claimed |
| WO-2003075010-A2 | NON-PEPTIDE IMMUNOLOGIC TRACER PRECURSORS COMPRISING A TYROSYL-(X)N OR LYSINE-(X)N TYROSINE MOTIF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- (FR) | 2003-09-12 | — | — | WO | claimed |
| WO-2003020206-A2 | USE OF ATAZANAVIR IN HIV THERAPY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| US-20030045501-A1 | Use of atazanavir in HIV therapy | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-06 | — | — | US | claimed |
| US-6528037-B2 | Via administering HIV protease inhibitor and glucose to rats and measuring the increases in plasma | TELIK, INC. | 2003-03-04 | — | — | US | claimed |
| US-20020151542-A1 | Method for determining whether a compound is an insulin receptor kinase activator | TELIK, INC. | 2002-10-17 | — | — | US | claimed |